Analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target on shares of Oncternal Therapeutics in a report on Tuesday, July 16th.
Read Our Latest Report on ONCT
Oncternal Therapeutics Stock Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.18 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same period in the prior year, the company posted ($4.00) earnings per share. Equities research analysts predict that Oncternal Therapeutics will post -11.63 EPS for the current year.
Institutional Trading of Oncternal Therapeutics
An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 16.05% of the stock is currently owned by institutional investors and hedge funds.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
See Also
- Five stocks we like better than Oncternal Therapeutics
- How to Invest in the FAANG Stocks
- Owens-Corning Stock: Good Value or Recession Red Flag?
- How to Invest in the Best Canadian StocksĀ
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- What is Insider Trading? What You Can Learn from Insider Trading
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.